BioCentury | Feb 3, 2021
Product Development

Big gain for Cassava on little efficacy data in Alzheimer’s

...NASDAQ:BIIB) enrolled over 1,600 patients each.Simufilam is not an amyloid-targeted agent. The small molecule stabilizes FLNA...
...the development of neuroinflammation. Cassava reported positive biomarker data for the molecule in 2019.TARGETSFLNAFilamin A Selina...
BioCentury | Apr 1, 2020
Distillery Therapeutics

FLNA identified as a target for epilepsy associated with focal cortical dysplasia type II

...DISEASE CATEGORY: Neurology INDICATION: Epilepsy Inhibiting the actin-binding protein FLNA could prevent or treat epilepsy associated...
...treat epilepsy associated with focal cortical dysplasia type II, a cerebral developmental malformation. Levels of FLNA...
...brain trauma. In a mouse model of focal cortical dysplasia type II, an shRNA against FLNA...
BioCentury | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

...to pharmas. Its pipeline has nine compounds. Lead candidate KA34 is a small molecule targeting FLNA...
...team discovered the target of KA34 to be the structural protein FLNA. The compound caused FLNA...
...subunit CHRM1 (HM1) - Muscarinic acetylcholine receptor M1 DPP-4 (CD26) - Dipeptidyl peptidase-4 FLNA - Filamin A Karen...
BioCentury | Feb 7, 2019
Clinical News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

...Alzheimer's disease and its lead AD candidate, PTI-125, which is a small molecule that binds filamin A (FLNA)...
BioCentury | Feb 5, 2019
Company News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

...Alzheimer's disease and its lead AD candidate, PTI-125, which is a small molecule that binds filamin A (FLNA)...
BioCentury | Dec 12, 2018
Distillery Therapeutics

Cardiovascular

...protein interaction assay in HeLa cells cultured under hypoxic conditions, cilnidipine decreased the mitochondrial fission-associated DNM1L-filamin A (FLNA)...
BioCentury | Oct 12, 2018
Emerging Company Profile

Spinogenix’s Spine Craft

...targeting an actin cytoskeleton-binding protein. PTI-125, which has completed Phase I, is thought to inhibit FLNA’s...
...Inc. San Diego, Calif. University of California San Diego, La Jolla, Calif. Targets FLNA - Filamin A Allison...
BioCentury | Aug 10, 2018
Clinical News

Pain shifting to AD following fourth Remoxy CRL

...Regulatory Update" ). Pain Therapeutics' lead AD candidate is PTI-125, a small molecule that binds filamin A (FLNA)...
...oxycodone extended release (PF-00345439) Business: Neurology Sandi Wong PTI-125 PTI-125DX Remoxy ER, oxycodone extended release (PF-00345439, PTI-821) Durect Corp. Cassava Sciences Inc. Filamin A (FLNA)...
BioCentury | Aug 6, 2018
Company News

Pain shifting to AD following fourth Remoxy CRL

...Remoxy's Approval" ). Pain Therapeutics' lead AD candidate is PTI-125, a small molecule that binds filamin A (FLNA)...
BioCentury | Dec 8, 2017
Clinical News

Pain reports Phase I data for AD candidate PTI-125

...NASDAQ:PTIE), Austin, Texas Product: PTI-125 Business: Neurology Molecular target: Filamin A (FLNA) Description: Small molecule that binds FLNA...
...Alzheimer's disease Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: NA Elizabeth S. Eaton PTI-125 Cassava Sciences Inc. Filamin A (FLNA) Clinical...
Items per page:
1 - 10 of 18